Mark Exley
Mark Exley, MS, PhD., is a translational Immunologist who has worked on cancer, inflammatory, infectious and other diseases. He has brought novel cell and antibody therapies to clinical trials in several settings. Mark is best known for his work on functional definition in health and disease and therapeutic evaluation of human and animal 'NKT' cell populations. He co-developed reagents to study and manipulate NKT cells clinically and in research, both in academia and industry. He was educated at Imperial College and Institute of Cancer Research, London University, UK. Mark was in Biotech, then Harvard Medical School Faculty and Beth Israel Deaconess Medical Center and since then Brigham & Women’s Hospital affiliate as well as Professor of Immunology at the University of Manchester, UK from 2013-2015. Mark was VP and is currently on the SAB and Senior advisor to iNKT company MiNK Therapeutics Inc. (previously AgenTus). Mark is also currently Imvax Inc. CSO, leading research into novel cancer immunotherapies, as well as retaining an honorary appointment at Brigham & Women’s Hospital.
Abstracts this author is presenting: